InvestorsHub Logo
Followers 3
Posts 1781
Boards Moderated 0
Alias Born 07/06/2004

Re: None

Monday, 05/18/2009 3:24:27 PM

Monday, May 18, 2009 3:24:27 PM

Post# of 1467
Therabel Pharma

....Dyloject Europe was sacrificed...

1/
in order to eliminate overhead as cash burn would take JAV into BK before Ereska ph3 and Dyloject Safety results.

The alternative was share dilution and the CEO stated..."No share dilution".

2/
We shall see if the previous seven trading days were short covering.

3/
Management's swap of salary for stock options underlines JAV's potential upside....hoping Gabe's #'s are conservative.